Literature DB >> 25755427

Portal hypertension and ascites in extramedullary hematopoiesis.

Pooja Amarapurkar1, Sunil Parekh2, Anjali Amarapurkar3, Deepak Amarapurkar1.   

Abstract

Myeloproliferative diseases (MPD) are clonal stem cell disorders which mainly include polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF). They are characterized by leucocytosis, thrombocytosis, erythrocytosis, splenomegaly, and bone marrow hypercellularity. This might also result in extramedullary hematopoiesis. Abdominal manifestation has been recognized as a feature of these disorders. Splenomegaly and hepatomegaly are fairly common as opposed to ascites which is rare. The MPDs mainly affect the hepatic circulatory systems. The common hepatic manifestations are Budd-Chiari syndrome (BCS), portal vein thrombosis (PVT), and nodular regenerative hyperplasia. A few other features seen in MPDs are caused by extramedullary hematopoiesis, increased hepatic blood flow, and secondary hemosiderosis from multiple blood transfusions. Portal hypertension is found in up to 7% of patients. We report a case of portal hypertension with ascites in a patient with extramedullary hematopoiesis treated with transjugular intrahepatic portocaval shunt (TIPS).

Entities:  

Keywords:  BCS, Budd-Chiari syndrome; ET, essential thrombocythemia; Extramedullary hematopoiesis; IMF, idiopathic myelofibrosis; IVC, inferior vena cava; MPD, myeloproliferative diseases; PV, polycythemia vera; PVT, portal vein thrombosis; SAAG, serum ascitic fluid albumin gradient; TIPS; TIPS, transjugular intrahepatic portocaval shunt; myeloproliferative diseases

Year:  2012        PMID: 25755427      PMCID: PMC3940412          DOI: 10.1016/S0973-6883(12)60107-8

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  3 in total

1.  Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.

Authors:  Christopher R Reilly; Daria V Babushok; Karlyn Martin; Jerry L Spivak; Michael Streiff; Ranjeeta Bahirwani; Jeffrey Mondschein; Brady Stein; Alison Moliterno; Elizabeth O Hexner
Journal:  Am J Hematol       Date:  2017-07-26       Impact factor: 10.047

Review 2.  Splanchnic Vein Thrombosis in the Myeloproliferative Neoplasms.

Authors:  Imo J Akpan; Brady Lee Stein
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

3.  The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib.

Authors:  Douglas Tremblay; Juan Putra; Alexander Vogel; Adam Winters; Ronald Hoffman; Thomas D Schiano; Maria Isabel Fiel; John O Mascarenhas
Journal:  Case Rep Hematol       Date:  2019-01-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.